-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2022-500574-34-00
4
2025-03-21
Waldenström’s Macroglobulinemia
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2024-513547-82-00
5
2025-03-11
Transthyretin Amyloidosis
-
2023-509234-19-00
4
2025-03-03
Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
-
2024-516380-81-00
4
2025-02-28
Treatment of IgAN
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2024-511775-15-00
4
2025-01-17
Immune system diseases
-
2024-510805-27-00
5
2025-01-09
Sickle Cell Disease and Thalassaemia
-
2024-515457-21-00
3
2024-12-30
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2022-500455-23-00
5
2024-12-11
Candidemia
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-507776-42-00
5
2024-11-14
Non-small cell lung cancer
-
2023-507178-41-00
9
2024-11-07
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell